Locus Cell Co., Ltd. (TPEX:6891)
Taiwan · Delayed Price · Currency is TWD 39.20
-1.05 (-2.61%)
Sep 18, 2026, 1:58 PM CST
Locus Cell Revenue
Locus Cell had revenue of 10.11M TWD in the half year ending June 30, 2026, with 1,494.79% growth. This brings the company's revenue in the last twelve months to 19.40M, up 274.71% year-over-year. In the year 2025, Locus Cell had annual revenue of 12.74M with 440.66% growth.
Revenue (ttm)
19.40M
Revenue Growth
+274.71%
P/S Ratio
408.48
Revenue / Employee
n/a
Employees
53
Market Cap
7.92B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.74M | 10.38M | 440.66% |
| Dec 31, 2024 | 2.36M | 1.95M | 480.30% |
| Dec 31, 2023 | 406.00K | -194.00K | -32.33% |
| Dec 31, 2022 | 600.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.45B |
| Adimmune | 1.37B |
| Savior Lifetec | 1.12B |
| PharmaEngine | 1.03B |
| TCM Biotech International | 701.63M |
| Tanvex BioPharma | 657.56M |
| TaiGen Biopharmaceuticals Holdings | 256.46M |
| Polaris Group | 67.95M |